Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/III Multi-center, Randomized and Positive Control Study to Evaluate IMC-002 Safety and Efficacy in in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

NCT06557174 is registered in ClinicalTrials.gov with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06557174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/III Multi-center, Randomized and Positive Control Study to Evaluate IMC-002 Safety and Efficacy in in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
Lead sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 10, 2024
Completion date
July 10, 2026
Enrollment
116 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder (nmosd)